Soon-Shiong immuno-oncology startup NantCell rakes in $57M
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.